AstraZeneca Buys Vaccine Startup; FDA Issues GLP-1 Safety Warning

AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning

The deal gives AstraZeneca a simpler way to make conjugate vaccines. Elsewhere, a psychedelic depression drug was submitted to the FDA and an autoimmune disease-focused biotech’s shares collapsed.

AstraZeneca acquires preclinical biotech Omniose (AZN:NYSE)

AstraZeneca acquires Omniose, a preclinical biotech whose single-cell method links bacterial polysaccharides to carrier proteins; terms undisclosed.

AstraZeneca bolsters vaccine pipeline with US-biotech ...

AstraZeneca Acquires Omniose, Adding Bioconjugation Platform to Vaccine Pipeline

AstraZeneca acquires Omniose, to bolster it's preclinical infectious disease programs.

Omniose Announces Its Acquisition by AstraZeneca

ST. LOUIS--(BUSINESS WIRE)--Omniose, a preclinical biotechnology company, today announced that it has been acquired by AstraZeneca. The acquisition follows a productive three-year exclusive research collaboration with AstraZeneca.Under the terms of the agreement, Omniose has become a wholly owned subsidiary of AstraZeneca and a part of the Infectious Disease Unit. The acquisition brings Omniose’s proprietary bioconjugation platform and expertise…